Soluble chemokine CCR5 receptor is present in human plasma

Kalinkovich, Alexander; Bentwich, Zvi

doi:10.1016/j.imlet.2004.07.014

Cited by 12 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tested parameters (CCL2 and CCR2) were measured with enzyme-linked immunosorbent assay (ELISA) (CCL2-R&D systems, Abingdon, United Kingdom; CCR2-EIAab Science, Wuhan, China), according to the manufacturer's instructions. ELISA system can specifically and selectively detect soluble chemokine receptors [ 16 – 18 ]. Plasma concentration of CA 15-3 was measured by chemiluminescent microparticle immunoassay (CMIA) (Abbott, Chicago, IL, USA).…”

Section: Methodsmentioning

confidence: 99%

Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

Lubowicka

Przylipiak

Zajkowska

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

The aim of this study was to investigate plasma levels and applicability of CCL2, CCR2, and tumor marker CA 15-3 in breast cancer (BC) patients and in relation to the control groups: patients with benign breast tumor and healthy subjects. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay (ELISA) and CA 15-3 by Chemiluminescent Microparticle Immunoassay (CMIA). The median levels of CCL2 in entire group of BC were significantly higher compared to the control groups, similarly as median levels of CA 15-3. CCR2 is a negative marker whose levels were significantly lower in BC group compared to healthy women. The concentration of CCL2 in BC increases with advancing tumor stage, while a median level of CCR2 decreases with advancing stage. CCL2 showed the highest value of sensitivity (SE) (64.95%) in entire BC group and also in early stages of disease. The highest specificity (SP) was obtained by CA 15-3 (85.71%). The area under the ROC curve (AUC) of CCR2 (0.7304) was the largest of all the tested parameters (slightly lower than CA 15-3) in the entire BC group, but a maximum range was obtained for the combination of all tested parameters with CA 15-3 (0.8271). In early stages of BC the highest AUC of all tested parameters was observed in CCL2 or CCR2 (stage I: 0.6604 and 0.6564; respectively; stage II: 0.7768, respectively, for CCR2). The findings of this study suggest that there may be applicability of CCL2, CCR2 in diagnosis of BC patients, particularly in conjunction with CA 15-3.

show abstract

Section: Methodsmentioning

confidence: 99%

Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

Lubowicka

Przylipiak

Zajkowska

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Although it is a reliable and reproducible method, it is fairly sensitive to a number o f factors such as temperature and pH which need to be optimised in order to produce quality results. Although CCR5 is usually a membrane bound receptor, a soluble form has previously been identified using a sandwich ELISA technique (Tsimanis 2005). This was found to be a 22kDa protein in contrast to the 40kDa membrane-bound form and seemed to affect an individual's susceptibility to infection with the HIV1 virus (see Chapter 4).…”

Section: Discussionmentioning

confidence: 99%

“…All antibodies and reagents were purchased and made up according to the method o f Tsimanis (Tsimanis 2005).…”

Section: Antibodies and Reagentsmentioning

confidence: 99%

The role of the CCR5 Δ32 polymorphism in abdominal aortic aneurysms

Sandford¹,

Bown²,

London³

et al. 2009

Int J Immunogenetics

View full text Add to dashboard Cite

All rights reserved INFORMATION TO ALL U SE R S The quality of this reproduction is d ep endent upon the quality of the copy submitted.In the unlikely event that the author did not sen d a com plete manuscript and there are m issing p a g es, th e se will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U 526187Published by ProQ uest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQ uest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode. ProQ uest LLC 789 East Eisenhow er Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ST A TEM EN T O F O R IG IN A LIT YI hereby declare that the work contained in this thesis is entirely my own, except where acknowledged, and has not been submitted for a degree to this or any other University. R.M.Sandford A B ST R A C T The Role o f the CCR5 A 32 Polymorphism in Abdominal Aortic Aneurysms By R.M.SandfordC-C Chemokine receptor 5 (CCR5) is involved in the regulation o f the inflammatory response. Abdominal aortic aneurysms (AAA) may arise as the result o f a chronic inflammatory process which is influenced by a genetic predisposition. The CCR5 gene harbours a 32 base pair deletion (the A32 polymorphism, rs333). The aim o f this study was to investigate the role o f the CCR5 A32 polymorphism in the development of AAA.A case control study was conducted including 285 patients with AAA and 273 control subjects. A blood sample was taken from each individual and DNA extracted. CCR5 genotype was determined using the polymerase chain reaction (PCR). Flow cytometry was used to investigate the biological activity o f the A32 polymorphism.There was no significant difference between the AAA and the control group in relation to the A32 allele frequency (AAA group 10%, control group 12%, P=0.82, chi squared analysis). There was also no significant difference in CCR5 genotype between groups (wild type homozygotes 82% in AAA group vs 77% in control group, heterozygotes 16% in AAA group vs 21% in control group, and A32 homozygotes 2% in both groups, P=0.33, chi squared analysis). The polymorphism was shown to be biologically active with the number o f A32 alleles correlating with cell expression of CCR5 as detected with flow cytometry (P=<0.05).This study demonstrates that the CCR5 A32 is a biologically active genetic polymorphism, however, there is no association between this polymorphism and AAA. Firstly, to Professor Rob Sayers for allowing me the opportunity to undertake this research and also for his supervision and support throughout the project. P U B L IC A T IO N S A R IS IN G FROM T H IS T H E S ISSandford DM Diabetes Mellitus DNAAlso, to Mr M iff Bown for his friendship, patience and encouragement in addition to providing statistical and scientific support. Demographic data 103 Table 7.2: Patient and control subject co-morbidity 105 Table 7.3: Patient and control group medication 106 Table 7.4: Univariate analysis of demog...

show abstract

“…2 Naturally occurring polymorphisms of the CCR5 gene generated by single point mutation, deletion of the function receptor, or reduced expression of the gene also play a role in the resistance to HIV-1 infection and progress of the disease. 13 The expression of CCR5 and CXCR4 appears to be extremely important in determining the susceptibility of T cells to HIV-1 infection. However, the infection rate and severity of the disease are controlled not only by the variability of CCR5 expression but also by the availability of an agonist.…”

Section: Introductionmentioning

confidence: 99%

“…However, the infection rate and severity of the disease are controlled not only by the variability of CCR5 expression but also by the availability of an agonist. 13 HIV pathogenesis involves both the response of cytotoxic T cells (CTL, as the cytolytic response) to viral proteins and the release of ␤-chemokines by CD8 ϩ T cells (the suppression response), which are important in the anti-HIV response. 11 In addition, CD4 ϩ T cells are also an important source of the ␤-chemokines, 14,15 especially among HIV-1-exposed but uninfected persons, 16,17 and among patients whose infection follows a slow progression to disease.…”

Section: Introductionmentioning

confidence: 99%

Successful HAART Is Associated with High B-Chemokine Levels in Chronic HIV Type 1-Infected Patients

Brito

Almeida

Gonsalez

et al. 2007

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Chemokine receptors are used by HIV-1 for entry into CD4+ T cells. The beta-chemokines are capable of inhibiting HIV replication. This study measured beta-chemokine macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels and determined the CCR5 and CXCR4 expression on T cells in HIV-1-infected patients treated with HAART. The time of known HIV infection and time of HAART use were similar between failure and successful groups. The CD4+ T cell nadir was 163 vs. 251 cells/mm3, p = 0.07, for failure and successful groups, respectively. The successfully treated group, when compared with the failure group, had a higher median CD4+ T cells count (667 vs. 257 cells/mm3; p = 0.003) as well as higher spontaneous MIP-1alpha (median of 4390 vs. 802 pg/ml, p = 0.03) and MIP-1beta (median of 2416 vs. 1117 pg/ml, p = 0.001) levels. The untreated patients had a higher number and intensity of CCR5- and CXCR4-expressing T cells. Higher levels of chemokines were not related to nadir CD4+ T and current CD8+ T cell counts. Successfully treated patients were able to produce higher amounts of beta-chemokines and normalize the coreceptor overexpression on T cells. These findings may have clinical implications, such as a new strategy of using chemokines as adjuvants in anti-HIV therapy.

show abstract

Soluble chemokine CCR5 receptor is present in human plasma

Cited by 12 publications

References 32 publications

Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

The role of the CCR5 Δ32 polymorphism in abdominal aortic aneurysms

Successful HAART Is Associated with High B-Chemokine Levels in Chronic HIV Type 1-Infected Patients

Contact Info

Product

Resources

About